Findings

What do systematic reviews say?

8 questions · 8 findings · 1 reviews

No studies found 1 · 12.5%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 25%Moderate 3 · 37.5%High 2 · 25%

Confirmed SARS‐CoV‐2 infection

The review found no eligible studies for this question.

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Confirmed symptomatic COVID‐19b

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 42175 participants
Moderate

Severe or critical COVID‐19

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 25452 participants
Moderate

All‐cause mortalityh

NVX‐CoV2373 – Novavax showed no clear difference in all‐cause mortalityh compared with placebo (low certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 0.9 [0.3, 2.68]
1 study · 29582 participants
Low

Systemic reactogenicity events

NVX‐CoV2373 – Novavax leads to higher systemic reactogenicity eventsj compared with placebo (high certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 1.21 [1.17, 1.25]
3 studies · 31063 participants
High

Any adverse eventm

NVX‐CoV2373 – Novavax probably leads to higher any adverse eventm compared with placebo (moderate certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 1.15 [1.05, 1.26]
5 studies · 46231 participants
Moderate

Serious adverse eventsm

NVX‐CoV2373 – Novavax showed no clear difference in serious adverse eventsm compared with placebo (low certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 0.92 [0.74, 1.14]
4 studies · 38802 participants
Low

Local reactogenicity events

NVX‐CoV2373 – Novavax leads to higher local reactogenicity eventsj compared with placebo (high certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 2.78 [1.99, 3.88]
3 studies · 31063 participants
High